Clinical Trial Update: A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) [Phase 3]

View source ↗

Summary

This clinical trial update notes that the Phase 3 MK-2400-001 study evaluating Ifinatamab Deruxtecan (I-DXd) in metastatic prostate cancer is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Ifinatamab Deruxtecan (Ifinatamab deruxtecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Prostate Cancer, Prostatic Neoplasms | Phase 3 | Status: RECRUITING